ESMO 2019 | KEYNOTE 522: pembrolizumab as neoadjuvant treatment for early TNBC

Peter Schmid, MD, PhD, FRCP, Barts Cancer Institute, London, UK, delivers an update on the Phase III KEYNOTE 522 study (NCT03036488) of pembrolizumab with chemotherapy vs placebo with chemotherapy as neoadjuvant treatment for early triple-negative breast cancer (TNBC). This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.